| Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals F Conti, F Buonfiglioli, A Scuteri, C Crespi, L Bolondi, P Caraceni, ... Journal of hepatology 65 (4), 727-733, 2016 | 1028 | 2016 |
| Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study F Piscaglia, G Svegliati‐Baroni, A Barchetti, A Pecorelli, S Marinelli, ... Hepatology 63 (3), 827-838, 2016 | 596 | 2016 |
| Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial P Caraceni, O Riggio, P Angeli, C Alessandria, S Neri, FG Foschi, ... The Lancet 391 (10138), 2417-2429, 2018 | 458 | 2018 |
| Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study A Vitale, P Burra, AC Frigo, F Trevisani, F Farinati, G Spolverato, M Volk, ... Journal of hepatology 62 (3), 617-624, 2015 | 224 | 2015 |
| Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? G Marisi, A Cucchetti, P Ulivi, M Canale, G Cabibbo, L Solaini, FG Foschi, ... World journal of gastroenterology 24 (36), 4152, 2018 | 169 | 2018 |
| Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC F Fornari, M Ferracin, D Trerè, M Milazzo, S Marinelli, M Galassi, ... PloS one 10 (10), e0141448, 2015 | 143 | 2015 |
| Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma A Cucchetti, F Trevisani, A Pecorelli, V Erroi, F Farinati, F Ciccarese, ... Journal of Hepatology 61 (2), 333-341, 2014 | 134 | 2014 |
| Development and validation of a new prognostic system for patients with hepatocellular carcinoma F Farinati, A Vitale, G Spolverato, TM Pawlik, T Huo, YH Lee, AC Frigo, ... PLoS medicine 13 (4), e1002006, 2016 | 131 | 2016 |
| Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection A Gramenzi, P Andreone, E Loggi, FG Foschi, C Cursaro, M Margotti, ... Journal of viral hepatitis 12 (5), 525-530, 2005 | 118 | 2005 |
| Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice EG Giannini, L Bucci, F Garuti, M Brunacci, B Lenzi, M Valente, E Caturelli, ... Hepatology 67 (5), 1784-1796, 2018 | 110 | 2018 |
| Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ... Oncotarget 7 (41), 67142, 2016 | 103 | 2016 |
| Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma G Cabibbo, S Petta, M Barbara, S Attardo, L Bucci, F Farinati, EG Giannini, ... Journal of hepatology 67 (1), 65-71, 2017 | 98 | 2017 |
| Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ... European Journal of Cancer 86, 106-114, 2017 | 94 | 2017 |
| Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon S Petta, G Cabibbo, M Barbara, S Attardo, L Bucci, F Farinati, EG Giannini, ... Alimentary pharmacology & therapeutics 45 (1), 160-168, 2017 | 93 | 2017 |
| Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome F Trevisani, E Castelli, FG Foschi, M Parazza, E Loggi, M Bertelli, ... Gut 50 (5), 707-712, 2002 | 90 | 2002 |
| A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma G Cabibbo, S Petta, M Barbàra, G Missale, R Virdone, E Caturelli, ... Liver International 37 (8), 1157-1166, 2017 | 88 | 2017 |
| Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA. LI. CA database A Vitale, G Svegliati-Baroni, A Ortolani, M Cucco, GV Dalla Riva, ... Gut 72 (1), 141-152, 2023 | 83 | 2023 |
| The changing scenario of hepatocellular carcinoma in Italy: an update F Garuti, A Neri, F Avanzato, A Gramenzi, D Rampoldi, P Rucci, F Farinati, ... Liver International 41 (3), 585-597, 2021 | 83 | 2021 |
| The evolutionary scenario of hepatocellular carcinoma in Italy: an update L Bucci, F Garuti, B Lenzi, A Pecorelli, F Farinati, EG Giannini, A Granito, ... Liver International 37 (2), 259-270, 2017 | 81 | 2017 |
| Determinants of alpha‐fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use EG Giannini, G Sammito, F Farinati, F Ciccarese, A Pecorelli, ... Cancer 120 (14), 2150-2157, 2014 | 79 | 2014 |
andrea casadei gardiniSan Raffaele university在 hsr.it 的电子邮件经过验证
